Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community (2015)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- Subjects: QUIMIOTERAPIA (EFEITOS ADVERSOS); NEOPLASIAS COLORRETAIS (TERAPIA); TOXICIDADE
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2015
- Source:
- Título: Journal of Clinical Oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 33, n. 3S , abstr. 760, 2015
- Conference titles: Gastrointestinal Cancers Symposium
-
ABNT
PROTASIO, Bruno Mendonca et al. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b. Acesso em: 24 fev. 2026. , 2015 -
APA
Protasio, B. M., Matutino, A. R. B., Lage, L. V., De Santana, I. A., Ramos, R. E. D. O., Caires-Lima, R., et al. (2015). Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b -
NLM
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2026 fev. 24 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b -
Vancouver
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2026 fev. 24 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
